Last 5 Days Trading Activity
|Date||Open Price||Close Price||High||Low||Volume|
Last 5 Days Short Activity
|Date||Short Volume||Total Volume||Short Percentage||Short Indicator|
* Short Mode
About Incyte Corp. (NASDAQ: INCY)
- Paul A. Friedman / CEO
- Robert B. Stein / President
- Robert B. Stein, PhD. MD, Director, is Chief Scientific Officer of Agenus Inc. Dr. Robert B. Stein leads Agenus Research, Preclinical Development and Translational Medicine functions. He helps shape clinical development strategy for vaccines and adjuvants. Additionally, he s leading integration of the Antibody acquisition, which includes the company s fully human antibody drug discovery and optimization technology platform, and portfolio of immune checkpoint antibody programs. Over his years of experience in the biopharmaceutical industry he played a pivotal role in bringing to the market Sustiva , Fablyn , Viviant , PanRetin , TargRetin , Promacta and Eliquis . Prior to joining Agenus he held executive management positions at Ligand Pharmaceuticals, DuPont Merck, Incyte Pharmaceuticals, Roche Palo Alto and KineMed. Dr. Stein began his career at Merck, Sharp and Dohme. He holds an MD and a PhD in Physiology amp Pharmacology from Duke University. Dr. Stein filed a personal voluntary bankruptcy petition under Chapter in August of and the bankruptcy was discharged in May .
- Michael Lack / COO
- John M. Vuko / CFO
Current Share Structure
- Market Cap: $14,206,173,304 - 05/16/2018
- Issue and Outstanding: 211,969,163 - 04/24/2018
Daily Technical Chart for (NASDAQ: INCY)
Stay tuned for daily updates and more on (NASDAQ: INCY)
More to come on (NASDAQ: INCY)
Do your DD and if you choose, be ready to go!
The Research: All source information contained in this email is from the public sources mentioned below.
Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in INCY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of INCY and does not buy, sell, or trade any shares of INCY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/